Md Ariful Islam/iStock via Getty Images
- Enliven Therapeutics (ELVN) and the US FDA have agreed on a design for the phase 3 trial of relcobatinib for chronic myeloid leukemia (CML) in those who have failed on prior treatments.
- The ENABLE-2 trial plans to enroll 450 adults
